Social media

Heading to ADPD 2026? Visit ICON at booth #29 to discuss how our early development and neuroscience teams support more informed decision making in neurodegenerative research. With in house early phase capabilities and ...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in Select Science explores the evolving NIT landscape, emerging regulat...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

In recognition of Rare Disease Day, join ICON’s Centre for Rare Diseases for an inspiring panel at our upcoming webinar on 3 March at 11 am EST. Hear directly from parent and patient leaders whose advocacy is driving f...

2025 signalled a reset for global biotech, with capital discipline, shifting partnership models and sharper execution shaping the year. Asia’s expanding R&D footprint further underlined the sector’s geographic diversific...

2025 signalled a reset for global biotech, with capital discipline, shifting partnership models and sharper execution shaping the year. Asia’s expanding R&D footprint further underlined the sector’s geographic diversific...

The EU Joint Clinical Assessment is already influencing how oncology therapies are developed and assessed across Europe. In this article, Dr. Liz O’Brien of ICON explains how #JCA is driving earlier evidence generation, ...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

A new qualitative study in BMC Musculoskeletal Disorders confirms the content validity of the Oswestry Disability Index instrument for individuals with Degenerative Disc Disease. The research shows high alignment betwe...